PMC:7455778 / 1591-3085 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-MONDO

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T9","span":{"begin":13,"end":14},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T10","span":{"begin":148,"end":153},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T11","span":{"begin":572,"end":573},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T12","span":{"begin":776,"end":777},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T13","span":{"begin":1182,"end":1185},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"}],"text":"Introduction\nA novel coronavirus (CoV) named severe acute respiratory syndrome coronavirus–2 (SARS-CoV-2) emerged from China in December 2019. This virus causes the coronavirus disease 2019 (COVID-19), which is having an extraordinary impact worldwide [1, 2].\nThe references in the medical literature regarding the ocular manifestations of this emerging disease are scarce so far and, despite the fact that ocular involvement is not well defined yet, some case reports have highlighted the presence of conjunctivitis [3].\nExisting data suggests that conjunctivitis is not a common manifestation associated with COVID-19 [4]. Nonetheless, characterizing conjunctival inflammation in this scenario could be of paramount importance in case it proves to be prevalent as it may be a frequent cause for seeking medical attention in patients possibly infected with SARS-CoV-2 [5].\nThe vast majority of studies published to date have been carried out in China. To the best of our knowledge, this is the first study of its kind in Europe. Given the current situation of the SARS-CoV-2 pandemic, describing the clinical characteristics of conjunctivitis associated with the novel coronavirus has relevant implications in the future identification of suspected COVID-19 patients and the differential diagnosis from other forms viral conjunctivitis. The purpose of this study was to evaluate the prevalence of conjunctivitis in hospitalized patients with COVID-19 and to describe its clinical presentation."}

LitCovid-PD-HP

{"project":"LitCovid-PD-HP","denotations":[{"id":"T12","span":{"begin":502,"end":516},"obj":"Phenotype"},{"id":"T13","span":{"begin":550,"end":564},"obj":"Phenotype"},{"id":"T14","span":{"begin":1129,"end":1143},"obj":"Phenotype"},{"id":"T15","span":{"begin":1322,"end":1336},"obj":"Phenotype"},{"id":"T16","span":{"begin":1398,"end":1412},"obj":"Phenotype"}],"attributes":[{"id":"A12","pred":"hp_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/HP_0000509"},{"id":"A13","pred":"hp_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/HP_0000509"},{"id":"A14","pred":"hp_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/HP_0000509"},{"id":"A15","pred":"hp_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/HP_0000509"},{"id":"A16","pred":"hp_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/HP_0000509"}],"text":"Introduction\nA novel coronavirus (CoV) named severe acute respiratory syndrome coronavirus–2 (SARS-CoV-2) emerged from China in December 2019. This virus causes the coronavirus disease 2019 (COVID-19), which is having an extraordinary impact worldwide [1, 2].\nThe references in the medical literature regarding the ocular manifestations of this emerging disease are scarce so far and, despite the fact that ocular involvement is not well defined yet, some case reports have highlighted the presence of conjunctivitis [3].\nExisting data suggests that conjunctivitis is not a common manifestation associated with COVID-19 [4]. Nonetheless, characterizing conjunctival inflammation in this scenario could be of paramount importance in case it proves to be prevalent as it may be a frequent cause for seeking medical attention in patients possibly infected with SARS-CoV-2 [5].\nThe vast majority of studies published to date have been carried out in China. To the best of our knowledge, this is the first study of its kind in Europe. Given the current situation of the SARS-CoV-2 pandemic, describing the clinical characteristics of conjunctivitis associated with the novel coronavirus has relevant implications in the future identification of suspected COVID-19 patients and the differential diagnosis from other forms viral conjunctivitis. The purpose of this study was to evaluate the prevalence of conjunctivitis in hospitalized patients with COVID-19 and to describe its clinical presentation."}

LitCovid-PD-GO-BP

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T1","span":{"begin":666,"end":678},"obj":"http://purl.obolibrary.org/obo/GO_0006954"}],"text":"Introduction\nA novel coronavirus (CoV) named severe acute respiratory syndrome coronavirus–2 (SARS-CoV-2) emerged from China in December 2019. This virus causes the coronavirus disease 2019 (COVID-19), which is having an extraordinary impact worldwide [1, 2].\nThe references in the medical literature regarding the ocular manifestations of this emerging disease are scarce so far and, despite the fact that ocular involvement is not well defined yet, some case reports have highlighted the presence of conjunctivitis [3].\nExisting data suggests that conjunctivitis is not a common manifestation associated with COVID-19 [4]. Nonetheless, characterizing conjunctival inflammation in this scenario could be of paramount importance in case it proves to be prevalent as it may be a frequent cause for seeking medical attention in patients possibly infected with SARS-CoV-2 [5].\nThe vast majority of studies published to date have been carried out in China. To the best of our knowledge, this is the first study of its kind in Europe. Given the current situation of the SARS-CoV-2 pandemic, describing the clinical characteristics of conjunctivitis associated with the novel coronavirus has relevant implications in the future identification of suspected COVID-19 patients and the differential diagnosis from other forms viral conjunctivitis. The purpose of this study was to evaluate the prevalence of conjunctivitis in hospitalized patients with COVID-19 and to describe its clinical presentation."}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T21","span":{"begin":0,"end":12},"obj":"Sentence"},{"id":"T22","span":{"begin":13,"end":142},"obj":"Sentence"},{"id":"T23","span":{"begin":143,"end":259},"obj":"Sentence"},{"id":"T24","span":{"begin":260,"end":521},"obj":"Sentence"},{"id":"T25","span":{"begin":522,"end":624},"obj":"Sentence"},{"id":"T26","span":{"begin":625,"end":873},"obj":"Sentence"},{"id":"T27","span":{"begin":874,"end":952},"obj":"Sentence"},{"id":"T28","span":{"begin":953,"end":1029},"obj":"Sentence"},{"id":"T29","span":{"begin":1030,"end":1337},"obj":"Sentence"},{"id":"T30","span":{"begin":1338,"end":1494},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Introduction\nA novel coronavirus (CoV) named severe acute respiratory syndrome coronavirus–2 (SARS-CoV-2) emerged from China in December 2019. This virus causes the coronavirus disease 2019 (COVID-19), which is having an extraordinary impact worldwide [1, 2].\nThe references in the medical literature regarding the ocular manifestations of this emerging disease are scarce so far and, despite the fact that ocular involvement is not well defined yet, some case reports have highlighted the presence of conjunctivitis [3].\nExisting data suggests that conjunctivitis is not a common manifestation associated with COVID-19 [4]. Nonetheless, characterizing conjunctival inflammation in this scenario could be of paramount importance in case it proves to be prevalent as it may be a frequent cause for seeking medical attention in patients possibly infected with SARS-CoV-2 [5].\nThe vast majority of studies published to date have been carried out in China. To the best of our knowledge, this is the first study of its kind in Europe. Given the current situation of the SARS-CoV-2 pandemic, describing the clinical characteristics of conjunctivitis associated with the novel coronavirus has relevant implications in the future identification of suspected COVID-19 patients and the differential diagnosis from other forms viral conjunctivitis. The purpose of this study was to evaluate the prevalence of conjunctivitis in hospitalized patients with COVID-19 and to describe its clinical presentation."}

2_test

{"project":"2_test","denotations":[{"id":"32860573-31986264-45244298","span":{"begin":256,"end":257},"obj":"31986264"},{"id":"32860573-28910427-45244299","span":{"begin":870,"end":871},"obj":"28910427"},{"id":"T55992","span":{"begin":256,"end":257},"obj":"31986264"},{"id":"T14243","span":{"begin":870,"end":871},"obj":"28910427"}],"text":"Introduction\nA novel coronavirus (CoV) named severe acute respiratory syndrome coronavirus–2 (SARS-CoV-2) emerged from China in December 2019. This virus causes the coronavirus disease 2019 (COVID-19), which is having an extraordinary impact worldwide [1, 2].\nThe references in the medical literature regarding the ocular manifestations of this emerging disease are scarce so far and, despite the fact that ocular involvement is not well defined yet, some case reports have highlighted the presence of conjunctivitis [3].\nExisting data suggests that conjunctivitis is not a common manifestation associated with COVID-19 [4]. Nonetheless, characterizing conjunctival inflammation in this scenario could be of paramount importance in case it proves to be prevalent as it may be a frequent cause for seeking medical attention in patients possibly infected with SARS-CoV-2 [5].\nThe vast majority of studies published to date have been carried out in China. To the best of our knowledge, this is the first study of its kind in Europe. Given the current situation of the SARS-CoV-2 pandemic, describing the clinical characteristics of conjunctivitis associated with the novel coronavirus has relevant implications in the future identification of suspected COVID-19 patients and the differential diagnosis from other forms viral conjunctivitis. The purpose of this study was to evaluate the prevalence of conjunctivitis in hospitalized patients with COVID-19 and to describe its clinical presentation."}

LitCovid-PMC-OGER-BB

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T9","span":{"begin":21,"end":32},"obj":"NCBITaxon:11118"},{"id":"T10","span":{"begin":45,"end":57},"obj":"SP_7"},{"id":"T11","span":{"begin":58,"end":69},"obj":"SP_7;UBERON:0001004"},{"id":"T12","span":{"begin":70,"end":92},"obj":"SP_7"},{"id":"T13","span":{"begin":94,"end":104},"obj":"SP_7"},{"id":"T14","span":{"begin":148,"end":153},"obj":"NCBITaxon:10239"},{"id":"T15","span":{"begin":165,"end":176},"obj":"NCBITaxon:11118"},{"id":"T16","span":{"begin":191,"end":199},"obj":"SP_7"},{"id":"T17","span":{"begin":315,"end":321},"obj":"UBERON:0000970"},{"id":"T18","span":{"begin":407,"end":413},"obj":"UBERON:0000970"},{"id":"T19","span":{"begin":611,"end":619},"obj":"SP_7"},{"id":"T20","span":{"begin":653,"end":665},"obj":"UBERON:0001811"},{"id":"T21","span":{"begin":858,"end":868},"obj":"SP_7"},{"id":"T22","span":{"begin":1065,"end":1075},"obj":"SP_7"},{"id":"T23","span":{"begin":1170,"end":1181},"obj":"NCBITaxon:11118"},{"id":"T24","span":{"begin":1250,"end":1258},"obj":"SP_7"},{"id":"T25","span":{"begin":1316,"end":1321},"obj":"NCBITaxon:10239"},{"id":"T26","span":{"begin":1443,"end":1451},"obj":"SP_7"},{"id":"T28589","span":{"begin":21,"end":32},"obj":"NCBITaxon:11118"},{"id":"T80906","span":{"begin":45,"end":57},"obj":"SP_7"},{"id":"T8842","span":{"begin":58,"end":69},"obj":"SP_7;UBERON:0001004"},{"id":"T34669","span":{"begin":70,"end":92},"obj":"SP_7"},{"id":"T86131","span":{"begin":94,"end":104},"obj":"SP_7"},{"id":"T55942","span":{"begin":148,"end":153},"obj":"NCBITaxon:10239"},{"id":"T44269","span":{"begin":165,"end":176},"obj":"NCBITaxon:11118"},{"id":"T59459","span":{"begin":191,"end":199},"obj":"SP_7"},{"id":"T66163","span":{"begin":315,"end":321},"obj":"UBERON:0000970"},{"id":"T47980","span":{"begin":407,"end":413},"obj":"UBERON:0000970"},{"id":"T45317","span":{"begin":611,"end":619},"obj":"SP_7"},{"id":"T40902","span":{"begin":653,"end":665},"obj":"UBERON:0001811"},{"id":"T64928","span":{"begin":858,"end":868},"obj":"SP_7"},{"id":"T21772","span":{"begin":1065,"end":1075},"obj":"SP_7"},{"id":"T93057","span":{"begin":1170,"end":1181},"obj":"NCBITaxon:11118"},{"id":"T1759","span":{"begin":1250,"end":1258},"obj":"SP_7"},{"id":"T71925","span":{"begin":1316,"end":1321},"obj":"NCBITaxon:10239"},{"id":"T48047","span":{"begin":1443,"end":1451},"obj":"SP_7"}],"text":"Introduction\nA novel coronavirus (CoV) named severe acute respiratory syndrome coronavirus–2 (SARS-CoV-2) emerged from China in December 2019. This virus causes the coronavirus disease 2019 (COVID-19), which is having an extraordinary impact worldwide [1, 2].\nThe references in the medical literature regarding the ocular manifestations of this emerging disease are scarce so far and, despite the fact that ocular involvement is not well defined yet, some case reports have highlighted the presence of conjunctivitis [3].\nExisting data suggests that conjunctivitis is not a common manifestation associated with COVID-19 [4]. Nonetheless, characterizing conjunctival inflammation in this scenario could be of paramount importance in case it proves to be prevalent as it may be a frequent cause for seeking medical attention in patients possibly infected with SARS-CoV-2 [5].\nThe vast majority of studies published to date have been carried out in China. To the best of our knowledge, this is the first study of its kind in Europe. Given the current situation of the SARS-CoV-2 pandemic, describing the clinical characteristics of conjunctivitis associated with the novel coronavirus has relevant implications in the future identification of suspected COVID-19 patients and the differential diagnosis from other forms viral conjunctivitis. The purpose of this study was to evaluate the prevalence of conjunctivitis in hospitalized patients with COVID-19 and to describe its clinical presentation."}

LitCovid-PubTator

PMC:7455778 / 1591-3085 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7455778 / 1591-3085 JSON TXT